Moderna says its low-dose COVID vaccine generates immune response in kids – CBC

Announcement comes as rival Pfizer awaits approval for its pediatric vaccine in both U.S. and Canada

Oct 25, 2021

Moderna said Monday that a low dose of its COVID-19 vaccine is safe and generates an immune response in six- to 11-year-olds as the manufacturer joins its rival Pfizer in moving toward expanding shots to children.

Pfizer-BioNTech’s kid-size COVID-19 vaccine doses are closer to widespread use. They are undergoing evaluation by the U.S. Food and Drug Administration (FDA) for children in nearly the same age group, five to 11, and could be available in the U.S. by early November. It is also awaiting approval from Health Canada for use in vaccinating Canadian kids.

Pfizer’s vaccine is already authorized for anyone 12 or older in both the U.S. and in Canada.

Here’s a children’s COVID-19 vaccine awaiting approval in Canada. What do we know about it?
FDA says kid-sized Pfizer vaccine doses appear highly effective, safe
Both Pfizer and Moderna have been studying lower doses for younger children.

Researchers tested two Moderna shots for the six- to 11-year-olds, given a month apart, that each contained half the dose given to adults.

Read more:

NationTalk Partners & Sponsors Learn More